Live Earnings Conference Call: Elanco Animal Health's Q1 2025 earnings call is happening now. Listen live.

Elanco Animal Health (ELAN) Financials

$9.53 -0.12 (-1.24%)

Closing price 05/6/2025 03:59 PM Eastern

Extended Trading

$10.11 +0.58 (+6.08%)

As of 08:03 AM Eastern

Compare

Annual Income Statements for Elanco Animal Health

This table shows Elanco Animal Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-48	-311	87	68	-574	-483	-78	-1,231	338
Consolidated Net Income / (Loss)	-48	-311	87	68	-574	-483	-78	-1,231	338
Net Income / (Loss) Continuing Operations	-48	-311	87	68	-574	-483	-78	-1,231	338
Total Pre-Tax Income	-22	-233	114	78	-677	-571	-72	-1,195	488
Total Operating Income	-25	-233	144	185	-705	-335	169	-918	83
Total Gross Profit	1,505	1,395	1,493	1,601	1,604	2,632	2,498	2,486	2,436
Total Revenue	2,914	2,889	3,067	3,071	3,271	4,764	4,411	4,417	4,439
Operating Revenue	2,914	2,889	3,067	3,071	3,271	4,764	4,411	4,417	4,439
Total Cost of Revenue	1,409	1,494	1,574	1,470	1,667	2,132	1,913	1,931	2,003
Operating Cost of Revenue	1,409	1,494	1,574	1,470	1,667	2,132	1,913	1,931	2,003
Total Operating Expenses	1,530	1,628	1,349	1,416	2,309	2,967	2,329	3,404	2,353
Selling, General & Admin Expense	785	780	735	760	997	1,403	1,265	1,285	1,314
Research & Development Expense	266	252	247	270	329	369	321	327	344
Amortization Expense	171	221	197	200	360	556	528	548	527
Other Operating Expenses / (Income)	-	-	41	-	-	5.00	32	75	18
Impairment Charge	-	-	-	-	-	0.00	0.00	1,042	0.00
Restructuring Charge	308	375	129	186	623	634	183	127	150
Total Other Income / (Expense), net	2.80	0.10	-30	-107	28	-236	-241	-277	405
Interest Expense	0.00	0.00	30	79	150	236	241	277	235
Other Income / (Expense), net	2.80	0.10	-	-28	178	-	0.00	0.00	640
Income Tax Expense	26	78	28	10	-103	-88	6.00	36	150
Basic Earnings per Share	($0.16)	($1.06)	$0.28	$0.18	($1.30)	($0.99)	($0.16)	($2.50)	$0.68
Weighted Average Basic Shares Outstanding	293.30M	293.30M	313.70M	369M	441.40M	487.20M	488.30M	492.30M	494M
Diluted Earnings per Share	($0.16)	($1.06)	$0.28	$0.18	($1.30)	($0.99)	($0.16)	($2.50)	$0.68
Weighted Average Diluted Shares Outstanding	293.30M	293.30M	313.70M	370.30M	441.40M	487.20M	488.30M	492.30M	497.30M
Weighted Average Basic & Diluted Shares Outstanding	293.30M	293.30M	313.70M	398.53M	472.17M	473.19M	491.54M	492.97M	494.61M

This table shows Elanco Animal Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-65	-54	103	-97	-1,096	-141	32	-50	364	-8.00
Consolidated Net Income / (Loss)	-65	-54	103	-97	-1,096	-141	32	-50	364	-8.00
Net Income / (Loss) Continuing Operations	-65	-54	103	-97	-1,096	-141	32	-50	364	-8.00
Total Pre-Tax Income	-44	-89	108	-79	-1,097	-127	12	-32	559	-51
Total Operating Income	16	-30	181	-5.00	-1,016	-78	78	33	618	-646
Total Gross Profit	554	536	763	623	581	519	690	689	538	519
Total Revenue	1,026	984	1,257	1,057	1,068	1,035	1,205	1,184	1,030	1,020
Operating Revenue	1,026	984	1,257	1,057	1,068	1,035	1,205	1,184	1,030	1,020
Total Cost of Revenue	472	448	494	434	487	516	515	495	492	501
Operating Cost of Revenue	472	448	494	434	487	516	515	495	492	501
Total Operating Expenses	538	566	582	628	1,597	597	612	656	-80	1,165
Selling, General & Admin Expense	298	301	327	353	313	292	337	354	323	300
Research & Development Expense	78	80	81	81	86	79	87	89	87	81
Amortization Expense	128	130	134	136	140	138	133	131	133	130
Other Operating Expenses / (Income)	8.00	-	-	23	0.00	-	9.00	2.00	-640	647
Restructuring Charge	26	31	40	35	16	36	46	80	17	7.00
Total Other Income / (Expense), net	-60	-59	-73	-74	-81	-49	-66	-65	-59	595
Interest Expense	60	62	64	74	72	67	66	65	58	46
Income Tax Expense	21	-35	5.00	18	-1.00	14	-20	18	195	-43
Basic Earnings per Share	($0.13)	($0.11)	$0.21	($0.20)	($2.22)	($0.29)	$0.06	($0.10)	$0.74	($0.02)
Weighted Average Basic Shares Outstanding	488.40M	488.30M	491.10M	492.60M	492.70M	492.30M	493.20M	494.20M	494.30M	494M
Diluted Earnings per Share	($0.13)	($0.11)	$0.21	($0.20)	($2.22)	($0.29)	$0.06	($0.10)	$0.73	($0.01)
Weighted Average Diluted Shares Outstanding	488.40M	488.30M	492.80M	492.60M	492.70M	492.30M	496M	494.20M	497.70M	497.30M
Weighted Average Basic & Diluted Shares Outstanding	474.21M	491.54M	492.55M	492.68M	492.80M	492.97M	494.18M	494.33M	494.35M	494.61M

This table details how cash moves in and out of Elanco Animal Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-176	57	325	-333	161	132	-293	7.00	116
Net Cash From Operating Activities	156	174	487	224	-41	483	452	271	541
Net Cash From Continuing Operating Activities	156	174	487	224	-41	483	452	271	541
Net Income / (Loss) Continuing Operations	-48	-311	87	68	-574	-483	-78	-1,231	338
Consolidated Net Income / (Loss)	-48	-311	87	68	-574	-483	-78	-1,231	338
Depreciation Expense	254	318	296	314	517	716	682	694	662
Non-Cash Adjustments To Reconcile Net Income	119	116	146	82	-146	263	367	1,177	-499
Changes in Operating Assets and Liabilities, net	-169	50	-41	-241	72	-77	-519	-369	40
Net Cash From Investing Activities	-182	-965	-127	-235	-4,779	-530	-179	-169	1,158
Net Cash From Continuing Investing Activities	-182	-965	-127	-235	-4,779	-530	-179	-169	1,158
Purchase of Property, Plant & Equipment	-110	-99	-135	-140	-135	-159	-171	-140	-147
Acquisitions	-45	-901	-2.00	-90	-5,177	-380	-13	-33	-55
Divestitures	-	-	0.00	0.00	435	-	0.00	0.00	1,294
Other Investing Activities, net	-34	-3.00	0.10	-5.00	26	9.00	5.00	4.00	66
Net Cash From Financing Activities	-150	848	-35	-305	4,954	210	-549	-83	-1,492
Net Cash From Continuing Financing Activities	-150	848	-35	-305	4,954	210	-549	-83	-1,492
Repayment of Debt	0.00	-0.80	-49	-113	-1,070	-854	-1,522	-683	-2,062
Issuance of Debt	0.00	0.00	2,500	0.00	4,804	500	988	600	570
Other Financing Activities, net	-150	848	-4,146	-192	0.00	64	-15	0.00	0.00
Effect of Exchange Rate Changes	-	-	-	-17	27	-31	-17	-12	-91

This table details how cash moves in and out of Elanco Animal Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-47	-115	-27	49	2.00	-17	-7.00	71	74	-22
Net Cash From Operating Activities	189	13	-145	61	198	157	2.00	200	162	177
Net Cash From Continuing Operating Activities	189	13	-145	61	198	157	2.00	200	162	177
Net Income / (Loss) Continuing Operations	-65	-54	103	-97	-1,096	-141	32	-50	364	-8.00
Consolidated Net Income / (Loss)	-65	-54	103	-97	-1,096	-141	32	-50	364	-8.00
Depreciation Expense	167	168	173	177	173	171	166	162	170	164
Non-Cash Adjustments To Reconcile Net Income	88	35	12	9.00	1,114	42	11	75	-605	20
Changes in Operating Assets and Liabilities, net	-1.00	-136	-433	-28	7.00	85	-207	13	233	1.00
Net Cash From Investing Activities	-37	-76	-55	-43	-36	-35	37	-33	1,244	-90
Net Cash From Continuing Investing Activities	-37	-76	-55	-43	-36	-35	37	-33	1,244	-90
Purchase of Property, Plant & Equipment	-36	-77	-24	-42	-33	-41	-24	-34	-42	-47
Acquisitions	-10	-2.00	-30	-	-3.00	-	-5.00	-	-8.00	-42
Other Investing Activities, net	9.00	3.00	-1.00	-1.00	-	6.00	0.00	1.00	66	-1.00
Net Cash From Financing Activities	-169	-84	174	39	-157	-139	-27	-93	-1,340	-32
Net Cash From Continuing Financing Activities	-170	-84	174	39	-157	-139	-27	-93	-1,340	-32
Repayment of Debt	-170	-69	-26	-11	-507	-139	-127	-213	-1,690	-32
Effect of Exchange Rate Changes	-	-	-	-	-3.00	-	-19	-3.00	8.00	-77

This table presents Elanco Animal Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	8,940	8,957	8,986	17,693	16,478	15,491	14,362	12,614
Total Current Assets	2,124	2,505	2,373	3,417	3,274	3,279	3,407	3,215
Cash & Equivalents	323	475	334	495	638	345	352	468
Accounts Receivable	602	709	890	1,077	1,028	1,002	1,010	886
Inventories, net	1,062	1,004	1,051	1,578	1,371	1,538	1,735	1,574
Prepaid Expenses	136	114	87	256	237	394	310	287
Plant, Property, & Equipment, net	920	922	955	1,316	1,055	999	1,026	993
Total Noncurrent Assets	5,896	5,529	5,657	12,960	12,149	11,213	9,929	8,406
Goodwill	2,969	2,958	2,990	6,225	6,172	5,993	5,094	4,414
Intangible Assets	2,673	2,505	2,483	6,387	5,587	4,842	4,494	3,681
Other Noncurrent Operating Assets	254	67	185	348	390	378	341	311
Total Liabilities & Shareholders' Equity	8,940	8,957	8,986	17,693	16,478	15,491	14,362	12,614
Total Liabilities	1,160	3,759	3,439	9,217	8,970	8,202	8,139	6,518
Total Current Liabilities	643	971	819	2,077	1,647	1,702	1,241	1,315
Short-Term Debt	0.00	29	25	555	294	388	38	44
Accounts Payable	204	474	239	501	416	390	270	296
Current Deferred Revenue	-	-	-	-	-	324	367	332
Current Employee Benefit Liabilities	89	99	100	144	185	146	157	177
Other Current Liabilities	350	369	455	877	752	454	409	466
Total Noncurrent Liabilities	517	2,789	2,620	7,140	7,323	6,500	6,898	5,203
Long-Term Debt	0.00	2,443	2,331	5,572	6,025	5,448	5,736	4,277
Noncurrent Deferred & Payable Income Tax Liabilities	252	115	101	900	765	662	567	449
Noncurrent Employee Benefit Liabilities	139	109	83	346	271	161	184	175
Other Noncurrent Operating Liabilities	126	122	107	322	262	229	411	302
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	7,780	5,198	5,547	8,476	7,508	7,289	6,223	6,096
Total Preferred & Common Equity	7,780	5,198	5,547	8,476	7,508	7,289	6,223	6,096
Total Common Equity	7,780	5,198	5,547	8,476	7,508	7,289	6,223	6,096
Common Stock	0.00	5,403	5,636	8,650	8,696	8,738	8,777	8,817
Retained Earnings	0.00	16	84	-477	-979	-1,057	-2,288	-1,950
Accumulated Other Comprehensive Income / (Loss)	-257	-222	-174	303	-209	-392	-266	-771

This table presents Elanco Animal Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	14,948	15,769	15,796	14,344	14,019	13,764	13,283
Total Current Assets	3,154	3,548	3,652	3,565	4,050	4,011	3,366
Cash & Equivalents	460	318	367	369	345	416	490
Accounts Receivable	1,028	1,264	1,225	1,135	1,078	1,080	904
Inventories, net	1,340	1,596	1,690	1,690	1,638	1,611	1,632
Prepaid Expenses	326	370	370	371	338	277	340
Plant, Property, & Equipment, net	936	1,000	1,007	992	949	949	979
Total Noncurrent Assets	10,858	11,221	11,137	9,787	9,020	8,804	8,938
Goodwill	5,716	6,061	6,040	4,902	4,478	4,480	4,625
Intangible Assets	4,766	4,791	4,678	4,475	4,196	4,000	4,011
Other Noncurrent Operating Assets	376	369	419	410	346	324	302
Total Liabilities & Shareholders' Equity	14,948	15,769	15,796	14,344	14,019	13,764	13,283
Total Liabilities	8,203	8,289	8,376	8,210	7,963	7,822	6,760
Total Current Liabilities	1,613	1,578	1,284	1,265	1,232	1,370	1,321
Short-Term Debt	394	381	39	39	38	213	44
Accounts Payable	350	381	354	296	302	291	259
Current Deferred Revenue	-	-	332	356	318	356	333
Other Current Liabilities	733	706	559	574	574	510	685
Total Noncurrent Liabilities	6,590	6,711	7,092	6,945	6,731	6,452	5,439
Long-Term Debt	5,507	5,639	6,023	5,870	5,727	5,463	4,313
Noncurrent Deferred & Payable Income Tax Liabilities	618	663	658	643	530	524	539
Other Noncurrent Operating Liabilities	225	245	411	432	474	465	587
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6,745	7,480	7,420	6,134	6,056	5,942	6,523
Total Preferred & Common Equity	6,745	7,480	7,420	6,134	6,056	5,942	6,523
Total Common Equity	6,745	7,480	7,420	6,134	6,056	5,942	6,523
Common Stock	8,724	8,744	8,752	8,763	8,777	8,790	8,804
Retained Earnings	-972	-954	-1,051	-2,147	-2,256	-2,306	-1,942
Accumulated Other Comprehensive Income / (Loss)	-1,007	-310	-281	-482	-465	-542	-339

This table displays calculated financial ratios and metrics derived from Elanco Animal Health's official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-0.84%	6.15%	0.14%	6.51%	45.64%	-7.41%	0.14%	0.50%
EBITDA Growth	0.00%	-63.02%	412.47%	7.35%	-83.05%	456.25%	91.24%	-126.32%	718.30%
EBIT Growth	0.00%	-938.39%	161.78%	9.26%	-435.67%	36.43%	150.45%	-643.20%	178.76%
NOPAT Growth	0.00%	-823.41%	166.88%	48.05%	-405.99%	52.48%	150.45%	-643.20%	108.95%
Net Income Growth	0.00%	-548.64%	127.84%	-21.39%	-944.12%	15.85%	83.85%	-1,478.21%	127.46%
EPS Growth	0.00%	-562.50%	126.42%	-35.71%	-822.22%	23.85%	83.84%	-1,462.50%	127.20%
Operating Cash Flow Growth	0.00%	11.48%	180.38%	-54.03%	-118.30%	1,278.05%	-6.42%	-40.04%	99.63%
Free Cash Flow Firm Growth	0.00%	0.00%	107.53%	-170.30%	-1,644.39%	109.58%	-21.71%	-6.62%	256.11%
Invested Capital Growth	0.00%	0.00%	-6.23%	8.07%	86.55%	-6.44%	-3.10%	-8.88%	-14.56%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-0.40%	11.98%	-0.52%	-2.82%	1.17%	-0.34%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	4.13%	869.23%	30.88%	3.78%	-25.14%	4.92%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	5.72%	-35.72%	38.53%	28.03%	-5.52%	11.06%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-7.02%	-81.56%	38.53%	28.03%	-5.52%	-82.25%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-27.51%	-132.95%	32.16%	40.91%	-7.60%	64.88%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-30.77%	-124.14%	34.87%	42.86%	-7.76%	70.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	37.46%	-5.60%	-123.01%	189.22%	-31.72%	113.39%	3.84%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-7.25%	614.91%	-64.11%	607.63%	9.05%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.39%	2.05%	-2.76%	4.87%	-0.25%	-4.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	51.64%	48.29%	48.68%	52.13%	49.04%	55.25%	56.63%	56.28%	54.88%
EBITDA Margin	7.96%	2.97%	14.34%	15.37%	2.45%	9.34%	19.29%	-5.07%	31.20%
Operating Margin	-0.86%	-8.05%	4.69%	6.02%	-21.55%	-7.03%	3.83%	-20.78%	1.87%
EBIT Margin	-0.77%	-8.05%	4.69%	5.11%	-16.11%	-7.03%	3.83%	-20.78%	16.29%
Profit (Net Income) Margin	-1.64%	-10.75%	2.82%	2.21%	-17.55%	-10.14%	-1.77%	-27.87%	7.61%
Tax Burden Percent	213.84%	133.58%	75.81%	87.18%	84.79%	84.59%	108.33%	103.01%	69.26%
Interest Burden Percent	100.00%	100.00%	79.40%	49.68%	128.46%	170.45%	-42.60%	130.17%	67.50%
Effective Tax Rate	0.00%	0.00%	24.19%	12.82%	0.00%	0.00%	0.00%	0.00%	30.74%
Return on Invested Capital (ROIC)	0.00%	-4.37%	1.51%	2.22%	-4.56%	-1.72%	0.91%	-5.26%	0.53%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	87.04%	-1.54%	-2.69%	-6.67%	-6.12%	-2.60%	-16.05%	6.58%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-3.62%	-0.17%	-0.95%	-3.63%	-4.32%	-1.97%	-12.96%	4.96%
Return on Equity (ROE)	0.00%	-7.99%	1.33%	1.27%	-8.19%	-6.04%	-1.05%	-18.22%	5.49%
Cash Return on Invested Capital (CROIC)	0.00%	-204.37%	7.94%	-5.54%	-64.97%	4.94%	4.06%	4.03%	16.24%
Operating Return on Assets (OROA)	0.00%	-2.60%	1.61%	1.75%	-3.95%	-1.96%	1.06%	-6.15%	5.36%
Return on Assets (ROA)	0.00%	-3.48%	0.97%	0.76%	-4.30%	-2.83%	-0.49%	-8.25%	2.51%
Return on Common Equity (ROCE)	0.00%	-7.99%	1.33%	1.27%	-8.19%	-6.04%	-1.05%	-18.22%	5.49%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-3.99%	1.66%	1.23%	-6.77%	-6.43%	-1.07%	-19.78%	5.54%
Net Operating Profit after Tax (NOPAT)	-18	-163	109	161	-494	-235	118	-643	57
NOPAT Margin	-0.61%	-5.64%	3.55%	5.25%	-15.09%	-4.92%	2.68%	-14.55%	1.30%
Net Nonoperating Expense Percent (NNEP)	0.00%	-91.41%	3.05%	4.90%	2.11%	4.40%	3.51%	10.78%	-6.05%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	0.90%	-5.36%	0.55%
Cost of Revenue to Revenue	48.36%	51.71%	51.32%	47.87%	50.96%	44.75%	43.37%	43.72%	45.12%
SG&A Expenses to Revenue	26.94%	26.99%	23.97%	24.75%	30.48%	29.45%	28.68%	29.09%	29.60%
R&D to Revenue	9.12%	8.71%	8.04%	8.79%	10.06%	7.75%	7.28%	7.40%	7.75%
Operating Expenses to Revenue	52.50%	56.34%	44.00%	46.11%	70.59%	62.28%	52.80%	77.07%	53.01%
Earnings before Interest and Taxes (EBIT)	-22	-233	144	157	-527	-335	169	-918	723
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	232	86	440	472	80	445	851	-224	1,385
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.19	2.22	1.98	1.71	1.79	0.80	1.18	0.98
Price to Tangible Book Value (P/TBV)	0.00	0.71	0.00	147.45	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.52	0.52	3.76	3.58	4.42	2.82	1.31	1.66	1.35
Price to Earnings (P/E)	0.00	0.00	133.27	161.54	0.00	0.00	0.00	0.00	17.71
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.75%	0.62%	0.00%	0.00%	0.00%	0.00%	5.65%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.16	1.91	1.72	1.43	1.45	0.88	1.10	0.99
Enterprise Value to Revenue (EV/Rev)	0.00	0.41	4.34	4.23	6.14	4.01	2.56	2.89	2.22
Enterprise Value to EBITDA (EV/EBITDA)	0.00	13.83	30.30	27.53	251.18	42.94	13.26	0.00	7.10
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	92.71	82.77	0.00	0.00	66.78	0.00	13.61
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	122.30	80.57	0.00	0.00	95.40	0.00	171.16
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	6.83	27.34	58.01	0.00	39.56	24.97	47.10	18.19
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	23.23	0.00	0.00	28.37	21.40	25.92	5.61
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.48	0.42	0.72	0.84	0.80	0.93	0.71
Long-Term Debt to Equity	0.00	0.00	0.47	0.42	0.66	0.80	0.75	0.92	0.70
Financial Leverage	0.00	-0.04	0.11	0.35	0.54	0.71	0.76	0.81	0.75
Leverage Ratio	0.00	1.15	1.38	1.67	1.90	2.14	2.16	2.21	2.19
Compound Leverage Factor	0.00	1.15	1.10	0.83	2.44	3.64	-0.92	2.88	1.48
Debt to Total Capital	0.00%	0.00%	32.23%	29.80%	41.96%	45.70%	44.46%	48.13%	41.48%
Short-Term Debt to Total Capital	0.00%	0.00%	0.38%	0.31%	3.80%	2.13%	2.96%	0.32%	0.42%
Long-Term Debt to Total Capital	0.00%	0.00%	31.86%	29.49%	38.16%	43.57%	41.51%	47.81%	41.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	67.77%	70.20%	58.04%	54.30%	55.54%	51.87%	58.52%
Debt to EBITDA	0.00	0.00	5.62	4.99	76.59	14.20	6.86	-25.78	3.12
Net Debt to EBITDA	0.00	0.00	4.08	4.26	70.26	12.77	6.45	-24.21	2.78
Long-Term Debt to EBITDA	0.00	0.00	5.56	4.94	69.65	13.54	6.40	-25.61	3.09
Debt to NOPAT	0.00	0.00	22.69	14.60	-12.42	-26.95	49.33	-8.99	75.16
Net Debt to NOPAT	0.00	0.00	16.48	12.46	-11.39	-24.23	46.42	-8.44	67.02
Long-Term Debt to NOPAT	0.00	0.00	22.43	14.45	-11.29	-25.69	46.05	-8.93	74.40
Altman Z-Score	0.00	1.22	2.44	2.54	1.08	1.16	0.77	0.60	1.06
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.30	2.58	2.90	1.65	1.99	1.93	2.75	2.44
Quick Ratio	0.00	1.44	1.22	1.50	0.76	1.01	0.79	1.10	1.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-7,620	574	-403	-7,034	674	527	492	1,753
Operating Cash Flow to CapEx	151.51%	284.92%	389.53%	160.00%	-65.08%	303.77%	264.33%	193.57%	368.03%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	19.38	-5.10	-46.89	2.85	2.19	1.78	7.46
Operating Cash Flow to Interest Expense	0.00	0.00	16.46	2.84	-0.27	2.05	1.88	0.98	2.30
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	12.24	1.06	-0.69	1.37	1.17	0.47	1.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.32	0.34	0.34	0.25	0.28	0.28	0.30	0.33
Accounts Receivable Turnover	0.00	4.80	4.68	3.84	3.33	4.53	4.35	4.39	4.68
Inventory Turnover	0.00	1.41	1.52	1.43	1.27	1.45	1.32	1.18	1.21
Fixed Asset Turnover	0.00	3.14	3.33	3.27	2.88	4.02	4.30	4.36	4.40
Accounts Payable Turnover	0.00	7.33	4.64	4.12	4.51	4.65	4.75	5.85	7.08
Days Sales Outstanding (DSO)	0.00	76.04	78.03	95.04	109.74	80.64	83.99	83.13	77.95
Days Inventory Outstanding (DIO)	0.00	259.55	239.62	255.10	287.79	252.44	277.52	309.33	301.49
Days Payable Outstanding (DPO)	0.00	49.79	78.59	88.51	81.01	78.50	76.89	62.38	51.57
Cash Conversion Cycle (CCC)	0.00	285.80	239.07	261.64	316.51	254.58	284.61	330.09	327.87
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	7,457	6,992	7,557	14,097	13,189	12,780	11,645	9,949
Invested Capital Turnover	0.00	0.77	0.42	0.42	0.30	0.35	0.34	0.36	0.41
Increase / (Decrease) in Invested Capital	0.00	7,457	-465	565	6,540	-908	-409	-1,135	-1,696
Enterprise Value (EV)	0.00	1,186	13,323	12,995	20,095	19,108	11,286	12,765	9,840
Market Capitalization	1,510	1,510	11,528	10,985	14,474	13,427	5,795	7,343	5,987
Book Value per Share	$0.00	$26.53	$14.22	$14.87	$17.96	$15.87	$15.37	$12.63	$12.33
Tangible Book Value per Share	$0.00	$7.29	($0.73)	$0.20	($8.76)	($8.99)	($7.48)	($6.83)	($4.04)
Total Capital	0.00	7,780	7,670	7,902	14,603	13,827	13,125	11,997	10,417
Total Debt	0.00	0.00	2,472	2,355	6,127	6,319	5,836	5,774	4,321
Total Long-Term Debt	0.00	0.00	2,443	2,331	5,572	6,025	5,448	5,736	4,277
Net Debt	0.00	-323	1,795	2,010	5,621	5,681	5,491	5,422	3,853
Capital Expenditures (CapEx)	103	61	125	140	63	159	171	140	147
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	1,157	886	1,234	1,389	1,283	1,620	1,852	1,476
Debt-free Net Working Capital (DFNWC)	0.00	1,481	1,563	1,579	1,895	1,921	1,965	2,204	1,944
Net Working Capital (NWC)	0.00	1,481	1,534	1,555	1,340	1,627	1,577	2,166	1,900
Net Nonoperating Expense (NNE)	30	148	22	93	81	249	196	588	-281
Net Nonoperating Obligations (NNO)	0.00	-323	1,795	2,010	5,621	5,681	5,491	5,422	3,853
Total Depreciation and Amortization (D&A)	254	318	296	315	607	780	682	694	662
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	40.06%	28.88%	40.18%	42.46%	26.93%	36.73%	41.93%	33.25%
Debt-free Net Working Capital to Revenue	0.00%	51.25%	50.97%	51.42%	57.93%	40.32%	44.55%	49.90%	43.79%
Net Working Capital to Revenue	0.00%	51.25%	50.03%	50.62%	40.97%	34.15%	35.75%	49.04%	42.80%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	($1.06)	$0.28	$0.18	($1.27)	($0.97)	$0.00	($2.50)	$0.68
Adjusted Weighted Average Basic Shares Outstanding	293.30M	293.30M	365.64M	369M	441.40M	487.20M	0.00	492.30M	494M
Adjusted Diluted Earnings per Share	($0.16)	($1.06)	$0.28	$0.18	($1.27)	($0.97)	$0.00	($2.50)	$0.68
Adjusted Weighted Average Diluted Shares Outstanding	293.30M	293.30M	365.64M	370.30M	441.40M	487.20M	0.00	492.30M	497.30M
Adjusted Basic & Diluted Earnings per Share	($0.16)	($1.06)	$0.28	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	293.30M	293.30M	313.70M	398.53M	472.17M	473.19M	0.00	492.97M	494.61M
Normalized Net Operating Profit after Tax (NOPAT)	198	100	207	323	-57	209	246	176	161
Normalized NOPAT Margin	6.80%	3.45%	6.74%	10.53%	-1.75%	4.39%	5.59%	3.98%	3.64%
Pre Tax Income Margin	-0.77%	-8.05%	3.72%	2.54%	-20.70%	-11.99%	-1.63%	-27.05%	10.99%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	4.85	1.99	-3.51	-1.42	0.70	-3.31	3.08
NOPAT to Interest Expense	0.00	0.00	3.68	2.04	-3.29	-0.99	0.49	-2.32	0.24
EBIT Less CapEx to Interest Expense	0.00	0.00	0.63	0.22	-3.93	-2.09	-0.01	-3.82	2.45
NOPAT Less CapEx to Interest Expense	0.00	0.00	-0.55	0.27	-3.71	-1.67	-0.22	-2.83	-0.38
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Elanco Animal Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-9.28%	-11.51%	2.53%	-10.04%	4.09%	5.18%	-4.14%	12.02%	-3.56%	-1.45%
EBITDA Growth	81.19%	28.97%	13.86%	-23.21%	-565.57%	-32.61%	-29.28%	13.37%	192.37%	-618.28%
EBIT Growth	122.86%	55.22%	35.43%	-109.43%	-6,506.25%	-160.00%	-54.65%	760.00%	160.20%	-728.21%
NOPAT Growth	122.86%	55.22%	86.66%	-110.64%	-6,450.00%	-160.00%	20.50%	760.00%	156.58%	-728.21%
Net Income Growth	37.50%	50.00%	101.96%	-870.00%	-1,586.15%	-161.11%	-68.93%	48.45%	133.21%	94.33%
EPS Growth	38.10%	52.17%	110.00%	-900.00%	-1,607.69%	-163.64%	-71.43%	50.00%	132.88%	96.55%
Operating Cash Flow Growth	112.36%	-94.17%	-133.87%	-80.45%	4.76%	1,107.69%	101.38%	227.87%	-18.18%	12.74%
Free Cash Flow Firm Growth	588.25%	-54.94%	15.56%	-150.67%	-114.35%	178.45%	549.99%	706.65%	946.60%	15.12%
Invested Capital Growth	-10.15%	-3.10%	-1.66%	3.30%	-4.20%	-8.88%	-17.88%	-19.37%	-11.00%	-14.56%
Revenue Q/Q Growth	-12.68%	-4.09%	27.74%	-15.91%	1.04%	-3.09%	16.43%	-1.74%	-13.01%	-0.97%
EBITDA Q/Q Growth	-18.30%	-24.59%	150.00%	-50.14%	-595.35%	110.92%	139.22%	-20.08%	303.59%	-161.25%
EBIT Q/Q Growth	-69.81%	-287.50%	673.33%	-102.91%	-20,400.00%	92.39%	213.04%	-57.69%	1,769.70%	-204.70%
NOPAT Q/Q Growth	-65.96%	-287.50%	922.00%	-102.03%	-20,220.00%	92.32%	530.64%	-88.89%	1,642.07%	-212.37%
Net Income Q/Q Growth	-550.00%	16.92%	290.74%	-194.17%	-1,029.90%	87.14%	122.70%	-256.25%	828.00%	-102.20%
EPS Q/Q Growth	-550.00%	15.38%	290.91%	-195.24%	-1,010.00%	86.94%	120.69%	-266.67%	830.00%	-101.37%
Operating Cash Flow Q/Q Growth	-39.42%	-93.12%	-1,215.38%	142.07%	224.59%	-20.71%	-98.73%	9,900.00%	-19.00%	9.26%
Free Cash Flow Firm Q/Q Growth	66.47%	-72.05%	1.71%	-207.06%	52.85%	642.37%	136.04%	-0.07%	-34.20%	-26.25%
Invested Capital Q/Q Growth	-4.02%	4.87%	3.15%	-0.51%	-10.99%	-0.25%	-7.04%	-2.31%	-1.75%	-4.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.00%	54.47%	60.70%	58.94%	54.40%	50.14%	57.26%	58.19%	52.23%	50.88%
EBITDA Margin	17.84%	14.02%	27.45%	16.27%	-79.78%	8.99%	20.25%	16.47%	76.41%	-47.25%
Operating Margin	1.56%	-3.05%	14.40%	-0.47%	-95.13%	-7.54%	6.47%	2.79%	60.00%	-63.33%
EBIT Margin	1.56%	-3.05%	13.68%	-0.47%	-95.97%	-7.54%	6.47%	2.79%	59.90%	-63.33%
Profit (Net Income) Margin	-6.34%	-5.49%	8.19%	-9.18%	-102.62%	-13.62%	2.66%	-4.22%	35.34%	-0.78%
Tax Burden Percent	147.73%	60.67%	95.37%	122.78%	99.91%	111.02%	266.67%	156.25%	65.12%	15.69%
Interest Burden Percent	-275.00%	296.67%	62.79%	1,580.00%	107.02%	162.82%	15.38%	-96.97%	90.60%	7.89%
Effective Tax Rate	0.00%	0.00%	4.63%	0.00%	0.00%	0.00%	-166.67%	0.00%	34.88%	0.00%
Return on Invested Capital (ROIC)	0.38%	-0.73%	4.59%	-0.11%	-24.37%	-1.91%	6.28%	0.74%	15.77%	-18.23%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.96%	-1.32%	3.38%	-1.77%	-31.38%	-3.49%	2.92%	-0.68%	14.96%	-8.65%
Return on Net Nonoperating Assets (RNNOA)	-0.75%	-0.99%	2.57%	-1.37%	-26.75%	-2.82%	2.26%	-0.52%	11.12%	-6.51%
Return on Equity (ROE)	-0.37%	-1.72%	7.16%	-1.48%	-51.13%	-4.73%	8.53%	0.22%	26.89%	-24.74%
Cash Return on Invested Capital (CROIC)	11.41%	4.06%	2.80%	-2.37%	-0.81%	4.03%	13.68%	15.63%	14.58%	16.24%
Operating Return on Assets (OROA)	0.45%	-0.84%	3.80%	-0.13%	-28.61%	-2.23%	1.90%	0.85%	19.32%	-20.84%
Return on Assets (ROA)	-1.83%	-1.51%	2.27%	-2.53%	-30.59%	-4.03%	0.78%	-1.28%	11.39%	-0.26%
Return on Common Equity (ROCE)	-0.37%	-1.72%	7.16%	-1.48%	-51.13%	-4.73%	8.53%	0.22%	26.89%	-24.74%
Return on Equity Simple (ROE_SIMPLE)	-1.96%	0.00%	-0.35%	-1.52%	-18.65%	0.00%	-21.50%	-21.12%	3.14%	0.00%
Net Operating Profit after Tax (NOPAT)	11	-21	173	-3.50	-711	-55	208	23	402	-452
NOPAT Margin	1.09%	-2.13%	13.73%	-0.33%	-66.59%	-5.28%	17.26%	1.95%	39.07%	-44.33%
Net Nonoperating Expense Percent (NNEP)	1.35%	0.59%	1.21%	1.66%	7.01%	1.58%	3.36%	1.42%	0.82%	-9.58%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.16%	-	-	-	-0.46%	-	-	-	-4.34%
Cost of Revenue to Revenue	46.00%	45.53%	39.30%	41.06%	45.60%	49.86%	42.74%	41.81%	47.77%	49.12%
SG&A Expenses to Revenue	29.04%	30.59%	26.01%	33.40%	29.31%	28.21%	27.97%	29.90%	31.36%	29.41%
R&D to Revenue	7.60%	8.13%	6.44%	7.66%	8.05%	7.63%	7.22%	7.52%	8.45%	7.94%
Operating Expenses to Revenue	52.44%	57.52%	46.30%	59.41%	149.53%	57.68%	50.79%	55.41%	-7.77%	114.22%
Earnings before Interest and Taxes (EBIT)	16	-30	172	-5.00	-1,025	-78	78	33	617	-646
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	183	138	345	172	-852	93	244	195	787	-482
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.87	0.80	0.62	0.67	0.90	1.18	1.32	1.20	1.11	0.98
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.30	1.31	1.04	1.15	1.27	1.66	1.84	1.59	1.63	1.35
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	35.42	17.71
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.82%	5.65%
Enterprise Value to Invested Capital (EV/IC)	0.93	0.88	0.78	0.81	0.95	1.10	1.24	1.17	1.07	0.99
Enterprise Value to Revenue (EV/Rev)	2.50	2.56	2.32	2.46	2.54	2.89	3.08	2.76	2.50	2.22
Enterprise Value to EBITDA (EV/EBITDA)	13.81	13.26	11.56	12.57	0.00	0.00	0.00	0.00	8.43	7.10
Enterprise Value to EBIT (EV/EBIT)	85.79	66.78	48.24	65.74	0.00	0.00	0.00	0.00	17.09	13.61
Enterprise Value to NOPAT (EV/NOPAT)	122.56	95.40	68.91	93.92	0.00	0.00	0.00	0.00	34.36	171.16
Enterprise Value to Operating Cash Flow (EV/OCF)	17.11	24.97	27.97	90.25	87.23	47.10	32.16	22.25	21.36	18.19
Enterprise Value to Free Cash Flow (EV/FCFF)	7.71	21.40	27.76	0.00	0.00	25.92	8.19	6.69	6.92	5.61
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.87	0.80	0.80	0.82	0.96	0.93	0.95	0.96	0.67	0.71
Long-Term Debt to Equity	0.82	0.75	0.75	0.81	0.96	0.92	0.95	0.92	0.66	0.70
Financial Leverage	0.78	0.76	0.76	0.77	0.85	0.81	0.77	0.77	0.74	0.75
Leverage Ratio	2.18	2.16	2.12	2.16	2.27	2.21	2.20	2.21	2.18	2.19
Compound Leverage Factor	-6.01	6.41	1.33	34.07	2.43	3.60	0.34	-2.15	1.98	0.17
Debt to Total Capital	46.66%	44.46%	44.59%	44.96%	49.07%	48.13%	48.77%	48.86%	40.05%	41.48%
Short-Term Debt to Total Capital	3.12%	2.96%	2.82%	0.29%	0.32%	0.32%	0.32%	1.83%	0.40%	0.42%
Long-Term Debt to Total Capital	43.55%	41.51%	41.77%	44.67%	48.74%	47.81%	48.45%	47.02%	39.64%	41.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	53.34%	55.54%	55.41%	55.04%	50.93%	51.87%	51.23%	51.14%	59.95%	58.52%
Debt to EBITDA	7.20	6.86	6.74	7.16	-33.01	-25.78	-17.26	-18.25	3.30	3.12
Net Debt to EBITDA	6.64	6.45	6.39	6.72	-30.95	-24.21	-16.23	-16.91	2.93	2.78
Long-Term Debt to EBITDA	6.72	6.40	6.31	7.11	-32.79	-25.61	-17.15	-17.57	3.27	3.09
Debt to NOPAT	63.86	49.33	40.19	53.46	-9.70	-8.99	-8.07	-8.25	13.45	75.16
Net Debt to NOPAT	58.89	46.42	38.06	50.22	-9.10	-8.44	-7.58	-7.64	11.94	67.02
Long-Term Debt to NOPAT	59.60	46.05	37.64	53.11	-9.64	-8.93	-8.01	-7.94	13.32	74.40
Altman Z-Score	0.77	0.73	0.72	0.71	0.46	0.79	0.95	0.88	1.11	0.70
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.96	1.93	2.25	2.84	2.82	2.75	3.29	2.93	2.55	2.44
Quick Ratio	0.92	0.79	1.00	1.24	1.19	1.10	1.16	1.09	1.06	1.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,388	388	395	-423	-199	1,080	2,565	2,563	1,686	1,244
Operating Cash Flow to CapEx	525.00%	16.88%	-604.17%	145.24%	600.00%	382.93%	8.33%	588.24%	385.71%	376.60%
Free Cash Flow to Firm to Interest Expense	23.14	6.26	6.17	-5.71	-2.77	16.13	38.86	39.43	29.08	27.04
Operating Cash Flow to Interest Expense	3.15	0.21	-2.27	0.82	2.75	2.34	0.03	3.08	2.79	3.85
Operating Cash Flow Less CapEx to Interest Expense	2.55	-1.03	-2.64	0.26	2.29	1.73	-0.33	2.55	2.07	2.83
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.29	0.28	0.28	0.28	0.30	0.30	0.29	0.30	0.32	0.33
Accounts Receivable Turnover	4.30	4.35	3.62	3.68	4.04	4.39	3.73	3.90	4.37	4.68
Inventory Turnover	1.45	1.32	1.29	1.22	1.23	1.18	1.21	1.22	1.21	1.21
Fixed Asset Turnover	4.59	4.30	4.47	4.39	4.53	4.36	4.48	4.59	4.52	4.40
Accounts Payable Turnover	5.03	4.75	4.85	4.99	5.77	5.85	5.72	6.24	7.27	7.08
Days Sales Outstanding (DSO)	84.84	83.99	100.91	99.31	90.41	83.13	97.92	93.65	83.55	77.95
Days Inventory Outstanding (DIO)	251.62	277.52	282.79	298.64	296.82	309.33	302.36	299.27	300.43	301.49
Days Payable Outstanding (DPO)	72.63	76.89	75.29	73.08	63.28	62.38	63.86	58.48	50.19	51.57
Cash Conversion Cycle (CCC)	263.83	284.61	308.41	324.87	323.95	330.09	336.42	334.44	333.78	327.87
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	12,186	12,780	13,182	13,115	11,674	11,645	10,825	10,575	10,390	9,949
Invested Capital Turnover	0.35	0.34	0.33	0.34	0.37	0.36	0.36	0.38	0.40	0.41
Increase / (Decrease) in Invested Capital	-1,377	-409	-222	419	-512	-1,135	-2,357	-2,540	-1,284	-1,696
Enterprise Value (EV)	11,325	11,286	10,323	10,650	11,078	12,765	13,443	12,391	11,129	9,840
Market Capitalization	5,884	5,795	4,621	4,955	5,538	7,343	8,023	7,131	7,262	5,987
Book Value per Share	$14.23	$15.37	$15.22	$15.06	$12.45	$12.63	$12.28	$12.02	$13.20	$12.33
Tangible Book Value per Share	($7.88)	($7.48)	($6.86)	($6.70)	($6.58)	($6.83)	($5.31)	($5.14)	($4.27)	($4.04)
Total Capital	12,646	13,125	13,500	13,482	12,043	11,997	11,821	11,618	10,880	10,417
Total Debt	5,901	5,836	6,020	6,062	5,909	5,774	5,765	5,676	4,357	4,321
Total Long-Term Debt	5,507	5,448	5,639	6,023	5,870	5,736	5,727	5,463	4,313	4,277
Net Debt	5,441	5,491	5,702	5,695	5,540	5,422	5,420	5,260	3,867	3,853
Capital Expenditures (CapEx)	36	77	24	42	33	41	24	34	42	47
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,475	1,620	2,033	2,040	1,970	1,852	2,511	2,438	1,599	1,476
Debt-free Net Working Capital (DFNWC)	1,935	1,965	2,351	2,407	2,339	2,204	2,856	2,854	2,089	1,944
Net Working Capital (NWC)	1,541	1,577	1,970	2,368	2,300	2,166	2,818	2,641	2,045	1,900
Net Nonoperating Expense (NNE)	76	33	70	94	385	86	176	73	38	-444
Net Nonoperating Obligations (NNO)	5,441	5,491	5,702	5,695	5,540	5,422	4,769	4,633	3,867	3,853
Total Depreciation and Amortization (D&A)	167	168	173	177	173	171	166	162	170	164
Debt-free, Cash-free Net Working Capital to Revenue	32.50%	36.73%	45.77%	47.18%	45.12%	41.93%	57.53%	54.27%	35.90%	33.25%
Debt-free Net Working Capital to Revenue	42.63%	44.55%	52.93%	55.67%	53.57%	49.90%	65.43%	63.54%	46.90%	43.79%
Net Working Capital to Revenue	33.95%	35.75%	44.35%	54.76%	52.68%	49.04%	64.56%	58.79%	45.91%	42.80%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.10)	($0.11)	$0.21	($0.20)	($2.22)	($0.29)	$0.06	($0.10)	$0.74	($0.02)
Adjusted Weighted Average Basic Shares Outstanding	488.40M	488.30M	491.10M	492.60M	492.70M	492.30M	493.20M	494.20M	494.30M	494M
Adjusted Diluted Earnings per Share	($0.10)	($0.11)	$0.21	($0.20)	($2.22)	($0.29)	$0.06	($0.10)	$0.73	($0.01)
Adjusted Weighted Average Diluted Shares Outstanding	488.40M	488.30M	492.80M	492.60M	492.70M	492.30M	496M	494.20M	497.70M	497.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	474.21M	491.54M	492.55M	492.68M	492.80M	492.97M	494.18M	494.33M	494.35M	494.61M
Normalized Net Operating Profit after Tax (NOPAT)	29	0.70	211	21	29	-29	87	79	413	-447
Normalized NOPAT Margin	2.87%	0.07%	16.77%	1.99%	2.75%	-2.84%	7.20%	6.68%	40.14%	-43.85%
Pre Tax Income Margin	-4.29%	-9.04%	8.59%	-7.47%	-102.72%	-12.27%	1.00%	-2.70%	54.27%	-5.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.27	-0.48	2.69	-0.07	-14.24	-1.16	1.18	0.51	10.64	-14.04
NOPAT to Interest Expense	0.19	-0.34	2.70	-0.05	-9.88	-0.81	3.15	0.36	6.94	-9.83
EBIT Less CapEx to Interest Expense	-0.33	-1.73	2.31	-0.64	-14.69	-1.78	0.82	-0.02	9.91	-15.07
NOPAT Less CapEx to Interest Expense	-0.41	-1.58	2.32	-0.61	-10.34	-1.43	2.79	-0.17	6.21	-10.85
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Elanco Animal Health's Financials

When does Elanco Animal Health's financial year end?

According to the most recent income statement we have on file, Elanco Animal Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Elanco Animal Health's net income changed over the last 8 years?

Elanco Animal Health's net income appears to be on an upward trend, with a most recent value of $338 million in 2024, falling from -$47.90 million in 2016. The previous period was -$1.23 billion in 2023. View Elanco Animal Health's forecast to see where analysts expect Elanco Animal Health to go next.

What is Elanco Animal Health's operating income?

Elanco Animal Health's total operating income in 2024 was $83 million, based on the following breakdown:

Total Gross Profit: $2.44 billion
Total Operating Expenses: $2.35 billion

How has Elanco Animal Health revenue changed over the last 8 years?

Over the last 8 years, Elanco Animal Health's total revenue changed from $2.91 billion in 2016 to $4.44 billion in 2024, a change of 52.4%.

How much debt does Elanco Animal Health have?

Elanco Animal Health's total liabilities were at $6.52 billion at the end of 2024, a 19.9% decrease from 2023, and a 461.9% increase since 2017.

How much cash does Elanco Animal Health have?

In the past 7 years, Elanco Animal Health's cash and equivalents has ranged from $323.40 million in 2017 to $638 million in 2021, and is currently $468 million as of their latest financial filing in 2024.

How has Elanco Animal Health's book value per share changed over the last 8 years?

Over the last 8 years, Elanco Animal Health's book value per share changed from 0.00 in 2016 to 12.33 in 2024, a change of 1,233.1%.

Related Companies

This page (NYSE:ELAN) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elanco Animal Health (ELAN) Financials

Frequently Asked Questions About Elanco Animal Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elanco Animal Health (ELAN) Financials

Annual Income Statements for Elanco Animal Health

Quarterly Income Statements for Elanco Animal Health

Annual Cash Flow Statements for Elanco Animal Health

Quarterly Cash Flow Statements for Elanco Animal Health

Annual Balance Sheets for Elanco Animal Health

Quarterly Balance Sheets for Elanco Animal Health

Annual Metrics and Ratios for Elanco Animal Health

Quarterly Metrics and Ratios for Elanco Animal Health

Frequently Asked Questions About Elanco Animal Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools